< Back to situations

[ORGANIZATION]

Opdivo

Featured in 2 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US]

Replimune melanoma therapy FDA approval

3 clusters · 18 sources · last updated

Latest: FDA approves new oncolytic viral therapy for anti‑PD‑1‑refractory melanoma

Following the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee vote of 10‑3 in late July 2026, the agency granted accelerated approval on 6 August 2026 to Replimune’s oncolytic herpes‑virus therapy RP1, marke

[ACTIVE] [BUSINESS] [GB] [US]

AstraZeneca–Bristol Myers merger talks

3 clusters · 69 sources · last updated

Latest: AstraZeneca and Bristol Myers Squibb Merger Talks Dismissed

In early August 2026 AstraZeneca and Bristol Myers Squibb were reported to be in talks about a $400 billion merger, prompting a 9 % drop in AstraZeneca’s share price and speculation about a possible headquarters move to